PMID- 22735864
OWN - NLM
STAT- MEDLINE
DCOM- 20130415
LR  - 20190606
IS  - 1678-4170 (Electronic)
IS  - 0066-782X (Linking)
VI  - 99
IP  - 1
DP  - 2012 Jul
TI  - Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart 
      failure with anemia.
PG  - 659-64
LID - S0066-782X2012005000055 [pii]
AB  - BACKGROUND: Levosimendan is known with its two-sided effects of strengthening 
      myofibril contraction without increasing myocardial oxygen demand. Anemia is a 
      deteriorating situation that causes increase of drug dosing in patients with 
      heart failure. OBJECTIVES: In this study, we compared the effectiveness of 
      levosimendan treatment in decompensated heart failure patients with or without 
      anemia. METHODS: Twenty-three anemic patients having class 3 or 4 heart failure 
      according to New York Heart Association (NYHA) and an ejection fraction of below 
      35% were included to the study. Another 23 patients with the same cardiac 
      diagnosis but without anemia served as control group. Twenty-four hours 
      levosimendan treatment was added to the traditional heart failure treatment of 
      these patients. Samples were taken to measure serum tumor necrotizing factor 
      alpha (TNF-alpha), aminoterminal pro-brain natriuretic peptide (NT-proBNP) and 
      matrix metalloproteinase-1 (MMP-1) levels before and after the administration. 
      RESULTS: There was no significant difference between serum TNF-alpha and MMP-1 
      levels before and after the treatment (p>0.05). Although NT-proBNP level 
      decreased in both groups after the treatment this was not statistically 
      significant (p=0.531 and p=0.913 for anemia and control groups respectively). 
      Significant restoration of functional capacity was seen in both groups assessed 
      according to NYHA (p<0.001 and p=0.001 for anemia and control groups 
      respectively). CONCLUSION: Levosimendan treatment shows similar effects in heart 
      failure patients with anemia to that of patients without anemia. However, the 
      early effect of this treatment on TNF-alpha, NT-proBNP and MMP-1 levels is not 
      evident. It provides significant improvement in functional capacity without 
      influence from anemia.
FAU - Buyuklu, Mutlu
AU  - Buyuklu M
AD  - Departamento de Cardiologia, Hospital Estadual de Erzincan, Erzincan. 
      mutlubuyuklu@gmail.com
FAU - Kurum, Akif Turhan
AU  - Kurum AT
FAU - Tatly, Ersan
AU  - Tatly E
FAU - Set, Turan
AU  - Set T
LA  - eng
LA  - por
PT  - Journal Article
DEP - 20120626
PL  - Brazil
TA  - Arq Bras Cardiol
JT  - Arquivos brasileiros de cardiologia
JID - 0421031
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 349552KRHK (Simendan)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
SB  - IM
MH  - Aged
MH  - Anemia/blood/*drug therapy/physiopathology
MH  - Cardiotonic Agents/pharmacology/therapeutic use
MH  - Chi-Square Distribution
MH  - Female
MH  - Heart Failure/blood/*drug therapy/physiopathology
MH  - Humans
MH  - Hydrazones/pharmacology/*therapeutic use
MH  - Infusions, Intravenous
MH  - Male
MH  - Matrix Metalloproteinase 1/*blood
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Pyridazines/pharmacology/*therapeutic use
MH  - Simendan
MH  - Statistics, Nonparametric
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*blood
EDAT- 2012/06/28 06:00
MHDA- 2013/04/16 06:00
CRDT- 2012/06/28 06:00
PHST- 2011/10/02 00:00 [received]
PHST- 2012/01/31 00:00 [accepted]
PHST- 2012/06/28 06:00 [entrez]
PHST- 2012/06/28 06:00 [pubmed]
PHST- 2013/04/16 06:00 [medline]
AID - S0066-782X2012005000055 [pii]
AID - 10.1590/s0066-782x2012005000055 [doi]
PST - ppublish
SO  - Arq Bras Cardiol. 2012 Jul;99(1):659-64. doi: 10.1590/s0066-782x2012005000055. 
      Epub 2012 Jun 26.